New COVID-19 vaccines from Moderna and Pfizer show effectiveness against dominant Eris variant

The Eris variant now accounts for over 17% of COVID-19 cases in the US.
Moderna and Pfizer have developed updated COVID-19 vaccines targeting the XBB.1.5 omicron subvariant.
Preliminary data indicates the new vaccines provide protection against both XBB.1.5 and Eris.
The vaccines are awaiting approval from regulators before being rolled out in the coming weeks.
Eris is designated a "variant of interest" by WHO but not expected to cause a major surge in infections.